Rodent Alzheimer Models
Rodent Alzheimer Models - Related Videos
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
0 Views •
Cited by 66 •
2011
One of the pathological characteristics of AD is the formation of Amyloid β protein positive neuritic plaques. In this protocol we describe two methods to detect neuritic plaques in transgenic AD model mice: immunohistochemical detection using the ABC and DAB method and fluorescent detection using thioflavin S staining method.
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
0 Views •
Cited by 4 •
2016
We developed a methodology for quantitative 3D in silico modeling (q3DISM) of cerebral amyloid-β (Aβ) phagocytosis by mononuclear phagocytes in rodent models of Alzheimer's disease. This method can be generalized for the quantitation of virtually any phagocytic event in vivo.
10:29
Principles of Rodent Surgery for the New Surgeon
0 Views •
Cited by 56 •
2011
Before attempting surgery, a new surgeon should have training in basic surgical techniques and concepts. This article will present basic surgical considerations with an emphasis on rodents.
02:47
Establishing an Alzheimer's Disease Model in Zebrafish Brain Through Amyloid Peptide Injection
0 Views •
2025
This video demonstrates the procedure of injecting monomeric amyloid peptides into the forebrain of adult zebrafish to generate amyloid toxicity, mimicking the neuronal damage seen in Alzheimer's...
01:29
Silver Staining of Neurofibrillary Tangles in Brain Sections from a Mouse Model of Alzheimer's Disease
0 Views •
2025
These sections contain neurofibrillary tangles—abnormal aggregates of tau protein found within hippocampal neurons.
FAQs
Engineered, treated, and selectively bred rodents can reproduce different aspects of Alzheimer’s disease rather than an identical disease course. One model may emphasize amyloid-β plaques, another tau pathology, and another synaptic dysfunction, neuroinflammation, or memory deficits. This feature-specific design helps investigators match a model to a particular biological question or therapeutic target.
Alzheimer’s disease includes interconnected molecular, cellular, neurological, and cognitive changes that do not all emerge together in a single rodent system. A model may reproduce pathology while incompletely representing other disease features. Consequently, researchers must define which aspect they are studying and avoid treating one model’s result as a complete representation of human disease.
Each measurement captures a different level of disease-related change. Molecular analyses identify biological alterations, brain imaging evaluates pathology or structure, behavioral tests examine memory-related performance, and electrophysiological measurements assess neural function. Considering these readouts together can show whether an intervention changes underlying pathology, brain activity, and cognition, rather than relying on one outcome alone.
Introducing human disease-associated genes can help investigators examine how specific genetic factors relate to Alzheimer’s-related changes in a controlled biological system. Depending on the model, researchers can then assess molecular abnormalities, amyloid-β or tau pathology, synaptic effects, neuroinflammation, or memory deficits. This approach supports focused studies of mechanisms and candidate interventions.
A study generally begins by selecting a model that expresses the feature relevant to the research question. Investigators then measure disease-related outcomes using molecular analyses, imaging, behavioral testing, or electrophysiology, administer or compare an intervention, and reassess those endpoints. Comparing pathology and function before and after treatment helps determine the intervention’s effects.
They are useful when researchers need controlled comparisons between disease-related changes and an intervention. Molecular analyses and imaging can support biomarker evaluation, while behavioral and electrophysiological measurements can indicate effects on cognition or neural function. The models therefore help compare candidate therapies and identify whether treatment-associated changes extend beyond a single biological or behavioral endpoint.
Rodent results provide controlled evidence about disease biology, biomarkers, and treatment effects, but they do not establish that the same outcome will occur in patients. Interpretation is strongest when findings are compared with human tissue and clinical data and examined alongside complementary model systems. This approach helps distinguish broadly supported mechanisms from effects limited to one rodent model.